☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November ~~5, 2021,~~7, 2022, the registrant had ~~59,666,519~~60,190,731 shares of common stock, $0.001 par value per share, outstanding.


	September 30, 2021			December 31, 2020			September 30, 2022			December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	25,217		$	17,287		$	53,381		$	30,436
Accounts receivable								123			10,000
Prepaid expenses		1,187			722			1,047			921
Other current assets		119			109			311			779
Total current assets		26,523			18,118			54,862			42,136
Property and equipment, net		283			416			437			238
Operating lease right-of-use asset		412			528			226			369
Restricted cash		160			260			160			160
Total assets	$	27,378		$	19,322		$	55,685		$	42,903
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	776		$	1,997		$	1,739		$	941
Accrued liabilities		2,996			1,582			2,945			3,312
Current portion of long-term debt		—			991
Current portion of operating lease liabilities		384			373			407			387
Deferred revenue		5,000			5,000			113			—
Total current liabilities		9,156			9,943			5,204			4,640
Liability related to the sales of future royalties, net								31,935			—
Operating lease liabilities		374			616			—			288
Total liabilities		9,530			10,559			37,139			4,928
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued at September 30, 2021 and December 31, 2020		—			—
Common stock, $0.001 par value; 100,000,000 shares authorized at September 30, 2021 and December 31, 2020; 59,626,519 and 51,860,941 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively		60			52
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at September 30, 2022 and December 31, 2021								—			—
Common stock, $0.001 par value; 200,000,000 and 100,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; 60,190,731 and 59,722,930 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively								60			60
Additional paid-in capital		291,988			264,578			297,261			293,406
Accumulated deficit		(274,200	)		(255,867	)		(278,775	)		(255,491	)
Total stockholders’ equity		17,848			8,763			18,546			37,975
Total liabilities and stockholders’ equity	$	27,378		$	19,322		$	55,685		$	42,903


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020			2022			2021			2022			2021
License and other revenue	$	3,074		$	3,432		$	3,888		$	7,883		$	266		$	3,074		$	997		$	3,888
Operating expenses:
Research and development		5,147			3,490			14,697			10,601			4,637			5,147			14,603			14,697
General and administrative		2,816			2,374			8,525			8,107			2,353			2,816			8,601			8,525
Total operating expenses		7,963			5,864			23,222			18,708			6,990			7,963			23,204			23,222
Loss from operations		(4,889	)		(2,432	)		(19,334	)		(10,825	)		(6,724	)		(4,889	)		(22,207	)		(19,334	)
Other income		2			0			1,001			0			194			2			220			1,001
Other expense		0			(1	)		0			(273	)
Non-cash interest expense on liability related to the sales of future royalties														(1,297	)		—			(1,297	)		—
Net loss	$	(4,887	)	$	(2,433	)	$	(18,333	)	$	(11,098	)	$	(7,827	)	$	(4,887	)	$	(23,284	)	$	(18,333	)
Net loss per share of common stock — basic and diluted	$	(0.08	)	$	(0.05	)	$	(0.32	)	$	(0.24	)	$	(0.13	)	$	(0.08	)	$	(0.39	)	$	(0.32	)
Weighted average shares outstanding — basic and diluted		59,474,346			46,976,649			58,095,080			45,653,068			60,188,541			59,474,346			60,134,821			58,095,080


	Nine Months Ended September 30, 2021												Nine Months Ended September 30, 2022
										Total												Total
	Common Stock				Additional		Accumulated			Stockholders'			Common Stock				Additional		Accumulated			Stockholders'
	Shares		Amount		Paid-In-Capital		Deficit			Equity			Shares		Amount		Paid-In-Capital		Deficit			Equity
Balance at December 31, 2020		51,860,941	$	52	$	264,578	$	(255,867	)	$	8,763
Issuance of common shares under a direct registered offering		4,209,050		4		11,074		—			11,078
Issuance of common shares under at-the-market sales agreement		1,186,579		2		3,247		—			3,249
Balance at December 31, 2021														59,722,930	$	60	$	293,406	$	(255,491	)	$	37,975
Exercise of stock options		62,493		—		38		—			38			22,727		—		3		—			3
Vesting and settlement of restricted stock units		227,754		—		—		—			—			375,331		—		—		—			—
Issuance of common shares under employee stock purchase plan		31,908		—		54		—			54			26,630		—		62		—			62
Share-based compensation expense		—		—		1,154		—			1,154			—		—		1,307		—			1,307
Net loss		—		—		—		(7,351	)		(7,351	)		—		—		—		(7,644	)		(7,644	)
Balance at March 31, 2021		57,578,725		58		280,145		(263,218	)		16,985
Issuance of common shares under at-the-market sales agreement		1,397,436		1		7,083		—			7,084
Balance at March 31, 2022														60,147,618		60		294,778		(263,135	)		31,703
Exercise of stock options		21,673		—		33		—			33			2,824		—		4		—			4
Vesting and settlement of restricted stock units		93,757		—		—		—			—
Share-based compensation expense		—		—		1,331		—			1,331			—		—		1,354		—			1,354
Net loss		—		—		—		(6,095	)		(6,095	)		—		—		—		(7,813	)		(7,813	)
Balance at June 30, 2021		59,091,591		59		288,592		(269,313	)		19,338
Issuance of common shares under at-the-market sales agreement		307,404		1		1,874		—			1,875
Exercise of stock options		100,194		—		149		—			149
Vesting and settlement of restricted stock units		93,757		—		—		—			—
Balance at June 30, 2022														60,150,442		60		296,136		(270,948	)		25,248
Issuance of common shares under employee stock purchase plan		33,573		—		57		—			57			40,289		—		51		—			51
Share-based compensation expense		—		—		1,316		—			1,316			—		—		1,074		—			1,074
Net loss		—		—		—		(4,887	)		(4,887	)		—		—		—		(7,827	)		(7,827	)
Balance at September 30, 2021		59,626,519	$	60	$	291,988	$	(274,200	)	$	17,848
Balance at September 30, 2022														60,190,731	$	60	$	297,261	$	(278,775	)	$	18,546


	Nine Months Ended September 30, 2020												Nine Months Ended September 30, 2021
										Total												Total
	Common Stock				Additional		Accumulated			Stockholders'			Common Stock				Additional		Accumulated			Stockholders'
	Shares		Amount		Paid-In-Capital		Deficit			Equity			Shares		Amount		Paid-In-Capital		Deficit			Equity
Balance at December 31, 2019		44,413,372	$	44	$	248,770	$	(237,657	)	$	11,157
Issuance of common shares under at-the-market sales agreement		455,186		1		1,192		—			1,193
Share-based compensation expense		—		—		1,001		—			1,001
Net loss		—		—		—		(2,911	)		(2,911	)
Balance at March 31, 2020		44,868,558		45		250,963		(240,568	)		10,440
Balance at December 31,2020														51,860,941	$	52	$	264,578	$	(255,867	)	$	8,763
Issuance of common shares under a direct registered offering														4,209,050		4		11,074		—			11,078
Issuance of common shares under at-the-market sales agreement		800,170		1		1,606		—			1,607			1,186,579		2		3,247		—			3,249
Exercise of stock options		58,333		—		72		—			72			62,493		—		38		—			38
Vesting and settlement of restricted stock units		512,550		—		—		—			—			227,754		—		—		—			—
Issuance of common shares under employee stock purchase plan		35,359		—		31		—			31			31,908		—		54		—			54
Share-based compensation expense		—		—		891		—			891			—		—		1,154		—			1,154
Net loss		—		—		—		(5,754	)		(5,754	)		—		—		—		(7,351	)		(7,351	)
Balance at June 30, 2020		46,274,970		46		253,563		(246,322	)		7,287
Balance at March 31, 2021														57,578,725		58		280,145		(263,218	)		16,985
Issuance of common shares under at-the-market sales agreement		1,382,564		2		2,283		—			2,285			1,397,436		1		7,083		—			7,084
Exercise of stock options		194,883		—		144		—			144			21,673		—		33		—			33
Vesting and settlement of restricted stock units		375,025		—		—		—			—			93,757		—		—		—			—
Share-based compensation expense		—		—		841		—			841			—		—		1,331		—			1,331
Net loss		—		—		—		(2,433	)		(2,433	)		—		—		—		(6,095	)		(6,095	)
Balance at September 30, 2020		48,227,442	$	48	$	256,831	$	(248,755	)	$	8,124
Balance at June 30, 2021														59,091,591		59		288,592		(269,313	)		19,338
Issuance of common shares under at-the-market sales agreement														307,404		1		1,874		—			1,875
Exercise of stock options														100,194		—		149		—			149
Vesting and settlement of restricted stock units														93,757		—		—		—			—
Issuance of common shares under employee stock purchase plan														33,573		—		57		—			57
Share-based compensation expense														—		—		1,316		—			1,316
Net loss														—		—		—		(4,887	)		(4,887	)
Balance at September 30, 2021														59,626,519	$	60	$	291,988	$	(274,200	)	$	17,848


	Nine Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2022			2021
Operating activities
Net loss	$	(18,333	)	$	(11,098	)	$	(23,284	)	$	(18,333	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense on liability related to the sales of future royalties								1,297			—
Depreciation		133			136			123			133
Share-based compensation expense		3,801			2,733			3,735			3,801
Gain on extinguishment of debt		(998	)		—			—			(998	)
Non-cash interest expense		—			59
Accretion of debt discount		—			129
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(475	)		1,441			9,952			(475	)
Other assets and liabilities		(115	)		(105	)		(125	)		(115	)
Accounts payable and accrued liabilities		200			(1,979	)		431			200
Deferred revenue								113			—
Net cash used in operating activities		(15,787	)		(8,684	)		(7,758	)		(15,787	)
Investing activities
Acquisition of property and equipment		—			(55	)		(155	)		—
Net cash provided by (used in) investing activities		—			(55	)
Net cash used in investing activities								(155	)		—
Financing activities
Proceeds from royalty purchase and sale agreement, net of $1.9 million of issuance costs								30,638			—
Proceeds from registered direct offering, net of issuance costs		11,078			—			—			11,078
Proceeds from at-the-market sales agreement, net of issuance costs		12,208			5,084			—			12,208
Proceeds from exercise of stock options		220			217			7			220
Proceeds from shares issued under employee stock purchase plan		111			31			113			111
Proceeds from long-term debt		—			991
Payments made on long-term debt		—			(5,340	)
Net cash provided by financing activities		23,617			983			30,758			23,617
Net increase (decrease) in cash, cash equivalents and restricted cash		7,830			(7,756	)
Net increase in cash, cash equivalents and restricted cash								22,845			7,830
Cash, cash equivalents and restricted cash, beginning of period		17,647			22,955			30,696			17,647
Cash, cash equivalents and restricted cash, end of period	$	25,477		$	15,199		$	53,541		$	25,477
Supplemental disclosure of noncash financing activities
Forgiveness of PPP Loan and accrued interest	$	998		$	—		$	—		$	998


	September 30,				September 30,
	2021		2020		2022		2021
Cash and cash equivalents	$	25,217	$	14,839	$	53,381	$	25,217
Restricted cash (including $100 for each period recorded in other current assets)		260		360
Restricted cash (including $100 recorded in other current assets at September 30, 2021)						160		260
Cash, cash equivalents and restricted cash at end of period	$	25,477	$	15,199	$	53,541	$	25,477

1. The Company

Clearside Biomedical, Inc. (the “Company”) is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Incorporated in the State of Delaware on May 26, 2011, the Company has its corporate headquarters in Alpharetta, Georgia.

The Company’s activities since inception have primarily consisted of developing product and technology rights, raising capital and performing research and development activities. The Company has no current source of revenue to sustain present activities, and does not expect to generate meaningful revenue until and unless the Company's licensees successfully commercialize XIPERE™, its other licensees receive regulatory approval and successfully commercializes its product candidates or the Company commercializes its product candidates either on its own or with a third party. The Company is subject to a number of risks and uncertainties similar to those of other life science companies at a similar stage of development, including, among others, the need to obtain adequate additional financing, successful development efforts including regulatory approval of products, compliance with government regulations, successful commercialization of potential products, protection of proprietary technology and dependence on key individuals.

Liquidity

The Company had cash and cash equivalents of $~~25.2~~53.4 million as of September 30, ~~2021. On January 6, 2021, the Company entered into a securities purchase agreement with certain institutional purchasers that purchased~~ ~~4.2~~ ~~million shares of its common stock in a registered direct offering at a price of $2.851~~ ~~per share. The Company raised net proceeds of $11.1~~ ~~million after deducting offering expenses. During the nine months ended September 30, 2021, the Company sold~~ ~~2.9~~ ~~million shares of its common stock for net proceeds of $12.2~~ ~~million under its at-the-market agreement with Cowen and Company, LLC.~~2022.

~~In August 2021,~~Historically, the Company ~~entered into an amendment to~~has funded its operations primarily through the ~~Arctic Vision License Agreement (as defined in Note 10 - License~~sale of common stock and ~~Other Agreements) to expand~~convertible preferred stock, the ~~territories covered by the~~issuance of long-term debt, and license to include India and the ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam). In September 2021, the Company entered into a second amendment to the Arctic Vision License Agreement to expand the territories covered by the license to include Australia and ~~New Zealand. The Company~~ ~~received an aggregate of $3.0~~ ~~million in consideration for the expansion of the licensed territory.~~

agreements. On October 25, 2021, the Company announced that the U.S. Food and Drug Administration (the "FDA") approved XIPERE® (triamcinolone acetonide injectable suspension) for the treatment of macular edema associated with uveitis, a form of eye inflammation. ~~The Company is entitled to an aggregate of $9.0~~ ~~million in milestone payments related to the approval of XIPERE from Arctic Vision (Hong Kong) Limited and Bausch + Lomb.~~ In ~~addition,~~January 2022, the Company ~~is entitled to receive~~received $10.0 million from Bausch + Lomb, a division of Bausch Health Companies, Inc. ("Bausch"), upon completion of pre-launch activities for ~~XIPERE.~~XIPERE pursuant to the license agreement granting Bausch ~~expects~~an exclusive license to ~~launch~~develop and commercialize XIPERE in the United States and Canada. Bausch launched XIPERE in the United States in the first quarter of 2022.

As further described in Note 5 to the financial statements on August 8, 2022, the Company entered into a Purchase and Sale Agreement (the "Purchase and Sale Agreement") pursuant to which it sold its rights to receive royalty and milestone payments due to the Company from XIPERE and certain SCS Microinjector license agreements subject to a cap which may be increased under certain circumstances. The Company received a payment of $32.1 million in September 2022, representing the $32.5 million to which the Company was entitled, net of certain of HCR's transaction-related expenses which the Company agreed to reimburse. There were additional issuance costs of $1.5 million related to the Purchase and Sale Agreement resulting in net proceeds of $30.6 million.

The Company has ~~funded its~~suffered recurring losses and negative cash flows from operations ~~primarily through~~since inception and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue. The Company has no current source of revenue to sustain present activities. The Company does not expect to generate other meaningful revenue until and unless the ~~sale of common stock and convertible preferred stock~~Company's licensees successfully commercialize XIPERE and the ~~issuance~~Company has fulfilled its obligations under the Purchase and Sale Agreement, its other licensees receive regulatory approval and successfully commercialize its product candidates, or the Company commercializes its product candidates either on its own or with a third party. In the absence of ~~long-term debt.~~ product or other revenues, the amount, timing, nature or source of which cannot be predicted, the Company’s losses will continue as it conducts its research and development activities.

The Company will continue to need to obtain additional financing to fund future operations, including completing the development, partnering and potential commercialization of its primary product candidates. The Company will need to obtain financing to complete the development and conduct ~~additional~~clinical trials for the regulatory approval of its product candidates if requested by regulatory ~~bodies, and completing the development of any product candidates.~~bodies. If such ~~products~~product candidates were to receive regulatory approval, the Company would need to obtain financing to prepare for the potential commercialization of its product candidates, if the Company decides to commercialize the products on its own.

The Company has suffered recurring losses and negative cash flows from operations since inception and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its licensees' commercialization of XIPERE. In the absence of product or other revenues, the amount, timing, nature or source of which cannot be predicted, the Company’s losses will continue as it conducts its research and development activities.

Based on ~~its current plans and forecasted expenses, the Company expects that~~ its cash and cash equivalents as of the filing date, November ~~10, 2021,~~9, 2022, its current plans and forecasted expenses the Company expects that it will ~~enable it~~be able to fund its planned operating expenses and capital expenditure requirements into ~~2023. This estimate assumes receipt of the $9.0~~ ~~million of milestone payments that the Company is entitled receive from its licensees as a result of the FDA approval of XIPERE. In addition, the estimate assumes receipt of the $10.0~~ ~~million milestone payment that the Company is entitled to receive from Bausch upon completion of pre-launch activities for XIPERE.~~2024. The Company has based this estimate on assumptions that may prove to be wrong, and it could exhaust its capital resources sooner than expected. Until the Company can generate sufficient revenue, the Company will need to finance future cash needs through public or private equity offerings, license agreements, debt financings or restructurings, collaborations, strategic alliances and marketing or distribution arrangements.

2. Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The Company's consolidated financial statements include the results of the financial operations of Clearside Biomedical, Inc. and its wholly-owned subsidiary, Clearside Royalty, LLC. a Delaware limited liability company, which was formed for the purposes of the transactions contemplated by the Purchase and Sale Agreement describe in Note 5.

The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

~~Unaudited Interim Financial Information~~

The accompanying balance sheet as of September 30, 2021, statements of operations for the three and nine months ended September 30, 2021 and 2020, statements of stockholders’ equity for the three and nine months ended September 30, 2021 and 2020 and statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in In the opinion of management, ~~reflect~~the Company has made all necessary adjustments, which include normal recurring adjustments necessary for ~~the~~a fair ~~presentation~~statement of the Company’s consolidated financial position ~~as of September 30, 2021, its~~and results of ~~its~~ operations for the three and nine months ended September 30, 2021 and 2020, its changes in stockholders’ equity for the three and nine months ended September 30, 2021 and 2020 and its cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are unaudited.interim periods presented. The results for the nine months ended September 30, ~~2021~~2022 are not indicative of results to be expected for the year ending December 31, ~~2021,~~2022, any other interim periods or any future year or period. These unaudited financial statements should be read in conjunction with the audited financial statements and related footnotes, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, the accounting for useful lives to calculate depreciation and amortization, clinical trial expense accruals, share-based compensation expense, ~~and~~ income tax valuation ~~allowance.~~allowance and the liability related to the sales of future royalties. Actual results could differ from these estimates.

Effects of COVID-19

The COVID-19 pandemic ~~has created~~continues to result in global ~~volatility,~~ economic ~~uncertainty and general market disruption.~~uncertainty. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require us to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to ~~our~~the Company's consolidated financial statements.

Revenue Recognition

The Company recognizes revenue from its contracts with customers under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC Topic 606”). The Company’s primary revenue arrangements are license agreements which typically include upfront payments, regulatory and commercial milestone payments and royalties based on future product sales. The arrangements may also include payments for the Company’s SCS Microinjector devices as well as payments for assistance and oversight of the customer’s use of the Company’s technology. In determining the amount of revenue to be recognized under these agreements, the Company performs the following steps: (i) identifies the promised goods and services to be transferred in the contract, (ii) identifies the performance obligations, (iii) determines the transaction price, (iv) allocates the transaction price to the performance obligations and (v) recognizes revenue as the performance obligations are satisfied.

The Company receives payments from its customers based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Research and Development Costs

Research and development costs are charged to expense as incurred and include:

•

employee-related expenses, including salaries, benefits, travel and share-based compensation expense for research and development personnel;

•

expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that conduct preclinical studies and clinical trials;

•

costs associated with preclinical and clinical development activities;

•

costs associated with submitting regulatory approval applications for the Company’s product candidates;

•

costs associated with training physicians on the suprachoroidal injection procedure and educating and providing them with appropriate product candidate information;

•

costs associated with technology and intellectual property licenses;

•

costs for the Company’s research and development facility; and

•

depreciation expense for assets used in research and development activities.

Costs for certain development activities, such as clinical ~~trials,~~trial activities, are recognized based on an evaluation of the estimated total costs for the clinical trial, progress to completion of specific tasks using data such as patient enrollment, pass through expenses, clinical site activations, data from the clinical sites or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual ~~arrangements,~~contracts and any subsequent amendments, which may differ from the patterns of costs incurred, and are reflected in the financial statements as prepaid or accrued expense.

Share-Based Compensation

Compensation cost related to share-based awards granted to employees, directors and consultants is measured based on the estimated fair value of the award at the grant date. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of restricted stock units granted is measured based on the market value of the Company’s common stock on the date of grant. Share-based compensation costs are expensed on a straight-line basis over the relevant vesting period.

Compensation cost related to shares purchased through the Company’s employee stock purchase plan, which is considered compensatory, is based on the estimated fair value of the shares on the offering date, including consideration of the discount and the look back period. The Company estimates the fair value of the shares using a Black-Scholes option pricing model. Compensation expense is recognized over the six-month withholding period prior to the purchase date.

All share-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the recipient's underlying ~~employees’ roles~~role within the Company.

Cash Equivalents

Cash equivalents consist of short-term, highly liquid investments with an original term of three months or less at the date of purchase.

Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits

The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash balances.

~~Recent Accounting Pronouncements~~Liability Related to the Sales of Future Royalties and Non-Cash Interest Expense

In December 2019, the FASB issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptionsThe Company recognizes a liability related to the ~~approach for intraperiod tax allocation,~~sales of future royalties under ASC 470-10 Debt and ASC 835-30 Interest - Imputation of Interest. The initial funds received by the ~~methodology for calculating income taxes~~Company pursuant to the terms of the Purchase and Sale Agreement were recorded as a liability and will be accreted under the effective interest method up to the estimated amount of future royalties and milestone payments to be made under the Purchase and Sale Agreement. The issuance costs were recorded as a direct deduction to the carrying amount of the liability and will be amortized under the effective interest method over the estimated period the liability will be repaid. The Company estimated the total amount of future royalty revenue and milestone payments to be generated over the life of the Purchase and Sale Agreement, and a significant increase or decrease in ~~an interim period~~these estimates could materially impact the liability balance and the ~~recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects~~related interest expense. If the timing of the ~~accounting for franchise taxes and enacted changes in tax laws~~receipt of royalty payments or ~~rates. These changes aim to improve~~milestones is materially different from the ~~overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing~~original estimates, the ~~disclosures. The~~ Company ~~adopted ASU 2019-12 on January 1, 2021,~~will prospectively adjust the effective interest and the ~~adoption did not have a material impact on its financial statements~~related amortization of the liability and related ~~disclosures.~~issuance costs.

3. Property and Equipment, Net

Property and equipment, net consisted of the following (dollar amounts in thousands):


	Estimated Useful Lives (Years)	September 30, 2021			December 31, 2020			Estimated Useful Lives (Years)	September 30, 2022			December 31, 2021
Furniture and fixtures	5	$	337		$	337		5	$	337		$	337
Machinery and equipment	5		176			176		5		343			176
Computer equipment	3		13			13		3		13			13
Leasehold improvements	Lesser of useful life or remaining lease term		667			667		Lesser of useful life or remaining lease term		667			667
Construction-in-process										155			—
			1,193			1,193				1,515			1,193
Less: Accumulated depreciation			(910	)		(777	)			(1,078	)		(955	)
		$	283		$	416			$	437		$	238

8.9. Share-Based Compensation

Share-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation.

Stock Options

The Company has granted stock option awards to employees, directors and consultants from its 2011 Stock Incentive Plan (the ~~“2011 Plan”~~"2011 Plan") and its 2016 Equity Incentive Plan (the “2016 Plan”). The estimated fair value of options granted is determined as of the date of grant using the Black-Scholes option pricing model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the awards.

Share-based compensation expense for options granted under the ~~2011 Plan and the~~ 2016 Plan is reflected in the consolidated statements of operations as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020		2022		2021		2022		2021
Research and development	$	391	$	290	$	1,182	$	882	$	431	$	391	$	1,245	$	1,182
General and administrative		525		384		1,461		1,176		327		525		1,381		1,461
Total	$	916	$	674	$	2,643	$	2,058	$	758	$	916	$	2,626	$	2,643

The following table summarizes the activity under the 2011 Plan and the 2016 Plan related to stock options during the nine months ended September 30, ~~2021:~~2022:

Weighted

Number of

Average

Shares

Exercise Price

Options outstanding at December 31, 2020

4,248,193

$
3.95

Granted

1,794,906

3.93

Exercised

(184,360
)

1.19

Forfeited

—

—

Options outstanding at September 30, 2021

5,858,739

4.03

Options exercisable at December 31, 2020

2,355,900

4.96

Options exercisable at September 30, 2021

3,081,524

4.58


				Weighted
	Number of			Average
	Shares			Exercise Price
Options outstanding at December 31, 2021		5,762,328		$	4.07
Granted		1,734,440			2.00
Exercised		(25,551	)		0.31
Forfeited		(252,612	)		2.78
Options outstanding at September 30, 2022		7,218,605			3.63

Options exercisable at December 31, 2021		3,148,502			4.59

Options exercisable at September 30, 2022		4,369,653			4.28

As of September 30, ~~2021,~~2022, the Company had $~~6.5~~5.1 million of unrecognized compensation expense related to unvested stock options issued under the 2016 Plan, which is expected to be recognized over a weighted average period of ~~2.7~~2.5 years.

The Company has granted restricted stock units (“RSUs”) to employees from the 2016 Plan. The shares underlying the RSU awards have vesting terms of ~~two to~~ four years from the date of grant subject to the employees’ continuous service and subject to accelerated vesting in specified circumstances. The fair value of the RSUs granted is measured based on the market value of the Company’s common stock on the date of grant and is recognized ratably over the requisite service period, which is generally the vesting period of the awards.

As of September 30, ~~2021,~~2022, the Company had $~~3.8~~3.4 million of unrecognized compensation expense related to the RSUs which is expected to be recognized over a weighted average period of ~~3.1~~ 2.5years.

The 2016 Employee Stock Purchase Plan (the “2016 ESPP”) became effective on June 1, 2016. The 2016 ESPP is considered a compensatory plan and the fair value of the discount and the look-back period are estimated using the Black-Scholes option pricing model and expense is recognized over the six-month withholding period prior to the purchase date.

During the nine months ended September 30, ~~2021,~~2022, the Company issued ~~65,481~~66,919 shares of common stock purchased under the 2016 ESPP.

9.10. Commitments and Contingencies

Lease Commitment Summary

In November 2016, the Company signed an office lease agreement to lease approximately 20,000 square feet of office space in Alpharetta, Georgia for its corporate headquarters. The lease agreement is for a 6.5 year term with a renewal option for one additional five-year term. Rental payments are $35,145 per month subject to an increase of 3% per year. Rent expense under this lease is recognized on a straight-line basis over the term of the lease. In addition, the lease agreement requires payment of the pro-rata share of the annual operating expenses associated with the premises.

The Company’s operating leases included on the consolidated balance sheet are as follows (in thousands):


	September 30, 2021
~~Operating lease right-of-use asset~~	$	~~412~~

~~Liabilities~~
~~Current portion of operating lease liabilities~~	$	~~384~~
~~Operating lease liabilities~~		~~374~~
~~Total operating lease liabilities~~	$	~~758~~


	September 30, 2022
Operating lease right-of-use asset	$	226

Liabilities
Current portion of operating lease liabilities	$	407
Operating lease liabilities		—
Total operating lease liabilities	$	407

The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company’s obligation to make payments over the lease term. The renewal option is not included in the calculation of the right-of-use asset and the lease liabilities as the Company ~~has not yet determined if~~is renewing the ~~Alpharetta, Georgia~~current lease ~~will be renewed.~~on to-be-determined terms. The present value of the lease payments is calculated using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. At September 30, ~~2021,~~2022, the Company’s weighted average discount rate was 11.0% and the weighted average lease term was ~~2.0~~1.0 years.

Minimum lease payments were as follows at September 30, ~~2021~~2022 (in thousands):


Year Ending December 31,
2021	$	99
2022		407			103
2023		316			316
Total minimum lease payments		822			419
Less imputed interest		(64	)		(12	)
Total operating lease liabilities	$	758		$	407

Equipment leases with an initial term of 12 months or less are not recorded with operating lease liabilities. The Company recognizes expense for these leases on a straight-line basis over the lease term. The equipment leases were deemed to be immaterial.

Operating lease cost was $62,000 for each of the three months ended September 30, ~~2021~~2022 and ~~2020,~~2021, and $185,000 for each of the nine months ended September 30, ~~2021~~2022 and ~~2020.~~2021. Variable lease cost was $24,000 for each of the three months ended September 30, ~~2021~~2022 and ~~2020,~~2021, and $71,000 for each of the nine months ended September 30, ~~2021~~2022 and ~~2020.~~2021. Short-term lease cost was $21,000 and $2,000 for ~~each of~~ the three months ended September 30, ~~2021~~2022 and ~~2020,~~2021, respectively, and $~~6,000~~64,000 and $~~10,000~~6,000 for the nine months ended

September 30, ~~2021~~2022 and ~~2020,~~2021, respectively. Cash payments included in operating activities on the statement of cash flows for operating lease liabilities were $~~293,000~~305,000 and $~~283,000~~293,000 for the nine months ended September 30, ~~2021~~2022 and ~~2020,~~2021, respectively.

Contract Service Providers

In the course of the Company’s normal business operations, it has agreements with contract service providers to assist in the performance of its research and development, clinical research and manufacturing. Substantially all of these contracts are on an as needed basis.

~~10.~~11. License and Other Agreements

Bausch + Lomb

On October 22, 2019, the Company entered into a License Agreement (as amended, the "Bausch License Agreement”) with ~~Bausch + Lomb, a division of Bausch Health Companies, Inc. (“Bausch”).~~Bausch. Pursuant to the Bausch License Agreement, the Company has granted an exclusive license to Bausch to develop, manufacture, distribute, promote, market and commercialize XIPERE using the Company’s proprietary ~~microinjector~~SCS Microinjector (the “Device”), as well as specified other steroids, corticosteroids and NSAIDs in combination with the Device (“Other Products,” and together with XIPERE, the “Products”), subject to specified exceptions, in the United States and Canada (the “Territory”) for the treatment of ophthalmology indications, including non-infectious uveitis.

~~On April 27, 2020, the Company and Bausch entered into an amendment to the Company’s License Agreement with Bausch dated October 22, 2019 (as amended, the “Bausch License Agreement”).~~

Pursuant to the Bausch License Agreement, Bausch ~~made~~paid the Company an upfront payment of $5.0 million ~~(the “Upfront Payment”)~~ in October 2019. In October 2021, the FDA approved XIPERE. The Company ~~is entitled to receive~~received $5.0 million from Bausch as a result of the approval. ~~An additional payment of~~In December 2021, $10.0 million ~~is due~~was recorded upon completion of pre-launch activities for ~~XIPERE.~~XIPERE and payment was received in January 2022. In addition, Bausch has agreed to pay up to an aggregate of $55.0 million in additional milestone payments upon the achievement of (i) specified regulatory approvals for specified additional indications of XIPERE and (ii) specified levels of annual net sales (as defined in the Bausch License Agreement). Further, during the applicable royalty term, the Company will also be entitled to receive tiered royalties at increasing percentages, from the high-teens to twenty percent, based on XIPERE achieving certain annual net sales thresholds in the Territory, in each case subject to reductions in specified circumstances; provided that the Company will not receive any royalties on the first $45.0 million of cumulative net sales of all products in the Territory. Bausch ~~expects to launch~~launched XIPERE in the United States in the first quarter of 2022.

The ~~Bausch License Agreement will expire upon expiration~~Company's rights to these royalties and milestone payments have been sold pursuant to the terms and conditions of the ~~royalty terms for all Products~~Purchase and ~~countries~~Sale Agreement described in the Territory, with each royalty term for a given Product and country ending on the latest of (i) the date of expiration of the last-to-expire valid claim of any licensed patent rights covering such Product in such country in the Territory, (ii) the date of the loss of regulatory exclusivity for such Product in such country in the Territory, or (iii) ten years from the later of the first sale of such Product in such country in the Territory. Following the payment of the Pre-Launch Milestone Payments, Bausch may also terminate the Bausch License Agreement for convenience upon 180 days’ written notice. In addition, the Company can terminate the Bausch License Agreement if Bausch commences a legal action challenging the validity, enforceability or scope of any of the licensed patents. Both parties may terminate the Bausch License Agreement (i) upon a material breach of the Bausch License Agreement, subject to a specified cure period and specified exceptions, or (ii) if the other party encounters bankruptcy or insolvency.

The Company was responsible for all development expenses for XIPERE in the Territory until the Company's New Drug Application ("NDA") was approved by the FDA, subject to specified exceptions, as well as manufacturing costs in connection with the NDA. The Company was also responsible for all clinical and development expenses conducted to satisfy the FDA’s requests in the

~~complete response letter issued on October 18, 2019 related~~Note 5 to the ~~NDA and any subsequent complete response letter related to the NDA (the “CRL-related expenses”).~~ ~~Following FDA approval of XIPERE, Bausch is responsible for all such expenses.~~

~~Due to the refund provisions in the License Agreement, the upfront payment of $5.0~~ ~~million received from Bausch was included on the balance sheet as deferred revenue as of September 30, 2021 and December 31, 2020. The refund provisions lapsed upon FDA approval of XIPERE. The $5.0~~ ~~million will be recognized as revenue in the fourth quarter of 2021.~~consolidated financial statements.

Arctic Vision (Hong Kong) Limited

On March 10, 2020, the Company entered into a License Agreement (the ~~“License~~“Arctic Vision License Agreement”) with Arctic Vision (Hong Kong) Limited (“Arctic Vision”). Pursuant to the Arctic Vision License Agreement, the Company has granted an exclusive license to Arctic Vision to develop, distribute, promote, market and commercialize XIPERE, subject to specified exceptions, in China, Hong Kong, Macau, Taiwan and South Korea (the “Arctic Territory”). Under the terms of the Arctic Vision License Agreement, neither party may commercialize XIPERE in the other party’s territory. Arctic Vision has agreed to use commercially reasonably efforts to pursue development and commercialization of XIPERE for indications associated with uveitis in the Arctic Territory. In addition, upon receipt of the Company’s consent, Arctic Vision will have the right, but not the obligation, to develop and commercialize XIPERE for additional indications in the Arctic Territory.

Pursuant to the Arctic Vision License Agreement, Arctic Vision paid the Company an upfront payment of $4.0 million in March 2020. In ~~addition, Arctic Vision has agreed to pay up to $31.5~~ ~~million in development~~December 2021, the Company received a milestone ~~payments for specified events, including~~payment of $4.0 million ~~upon~~following the receipt of FDA approval of XIPERE in the United ~~States~~States. In addition, Arctic Vision has agreed to pay the Company up to $22.5 million in development and sales ~~milestone payments for achievement of specified levels of net sales.~~milestones. Further, during the applicable royalty term, the Company will also be entitled to receive tiered royalties of 10ten to 12twelve percent of net sales based on achieving certain annual net sales thresholds in the Territory, subject to customary reductions, payable on a product-by-product and country-by-country basis, commencing at launch in such country and lasting until the latest of (i) the date that all valid claims within the licensed patent rights covering XIPERE have expired, (ii) the date of the loss of marketing or regulatory exclusivity of XIPERE in a given country, or (iii) ten years from the first commercial sale of XIPERE in a given country. The Company's rights to these royalties and milestone payments have been sold pursuant to the terms and conditions of the Purchase and Sale Agreement described in Note 5 to the consolidated financial statements.

In August 2021, the Company entered into an amendment to the Arctic Vision License Agreement to expand the territories covered by the license to include India and the ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam). In September 2021, the Company entered into a second amendment to the Arctic Vision License Agreement to expand the Arctic Territory to include Australia and New Zealand. The Company received an aggregate of $3.0 million in consideration for the expansion of the Arctic Territory.

Other

The Company periodically enters into short-term agreements with other customers to evaluate the potential use of its proprietary SCS Microinjector with third-party product candidates for the treatment of various diseases. Funds received from these agreements are recognized as revenue over the term of the agreement.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Certain statements contained in this Quarterly Report on Form 10-Q may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions, or the negative of such words or phrases, are intended to identify “forward-looking statements.” We have based these forward-looking statements on our current expectations and projections about future events. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those below and elsewhere in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission, or SEC, under the heading “Risk Factors”. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its potential impact on our business and the global economy. Statements made herein are as of the date of the filing of this Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim, any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes for the year ended December 31, ~~2020~~2021 appearing in our Annual Report on Form 10-K filed with the SEC on March ~~15, 2021.~~11, 2022.

We are a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, ~~(SCS~~or SCS®). Our novel SCS injection platform, utilizing our proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Our SCS injection platform can be used in conjunction with existing drugs designed for delivery to the SCS, novel therapies and future therapeutic innovations. We believe our proprietary suprachoroidal administration platform has the potential to become a standard for delivery of therapies intended to treat chorioretinal diseases.

We are leveraging our SCS injection platform by building an internal research and development pipeline targeting retinal diseases and by creating external collaborations with other companies. We are developing our own pipeline of small molecule product candidates for administration via our SCS Microinjector, and we also strategically partner with companies developing other ophthalmic therapeutic innovations to be administered using our SCS injection ~~platform with companies utilizing other ophthalmic therapeutic innovations.~~platform. Our first product, XIPERE™® (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration, or the FDA, in October 2021. Approval of XIPERE was a significant milestone for us as it is the first approved therapeutic delivered into the SCS, the first commercial product developed by us and the first therapy for macular edema associated with uveitis.

We believe that we are ~~leveraging our SCS injection platform by building an internal research and development pipeline targeting chorioretinal diseases and by~~ creating external collaborations with other companies. Using our suprachoroidal injection technology in conjunction with proprietary formulations of existing drugs as well as novel therapies, we believe we have created a broad therapeutic platform for developing product candidates to treat serious ~~back of the~~ eye diseases.

The current development status of our pipeline of internal product candidates and external collaborations is summarized in the chart below:

Our first product, XIPERE, ~~formerly known as CLS-TA,~~ is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide, or TA, for ~~administration via~~ suprachoroidal ~~injection.~~use. Corticosteroids are the standard of care in uveitis. They are effective at treating the inflammatory aspect of ocular disease, but when delivered locally, either topically as drops, intravitreally or by periocular injection, they have been associated with significant side effects, such as cataract formation or exacerbation and elevated intraocular pressure, or IOP, which can lead to glaucoma.

~~On October 25, 2021, we announced that~~ XIPERE is delivered into the ~~FDA~~suprachoroidal space via a novel route of administration utilizing our SCS Microinjector. XIPERE is approved ~~XIPERE~~by the FDA for the treatment of macular edema associated with uveitis. Uveitis is a set of ocular inflammatory conditions affecting approximately 350,000 patients in the United States and more than one million worldwide. Approximately one-third of uveitis patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp, straight-ahead vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location—anterior, intermediate, posterior or panuveitis. The uveitis market is expected to grow to nearly $550 million by 2024 in the United States, and over $1 billion globally.

We are ~~developing a~~evaluating options for potential submissions to regulatory agencies to seek regulatory approval of XIPERE for the treatment of patients with macular edema associated with uveitis in additional territories outside of territories licensed by Arctic Vison and Bausch.

CLS-AX, our most advanced product candidate, is our proprietary suspension of ~~axitinib, a~~the tyrosine kinase inhibitor, or TKI, axitinib for suprachoroidal injection ~~which~~delivered via our SCS Microinjector. CLS-AX is an inhibitor of vascular endothelial growth factor receptor-1, -2 and -3 that we ~~refer~~believe may benefit patients who respond sub optimally to current anti-VEGF therapies. We are developing CLS-AX for administration to the SCS as CLS-AX. In our preclinical studies, administration of CLS-AX through suprachoroidal injection was well tolerated and showed durability over several months, providing us with the opportunity to potentially reduce treatment burden and address a ~~primary need~~long-acting therapy for ~~neovascular age-related macular degeneration, or wet AMD, patients.~~retinal diseases.

In August 2020, we announced that the FDA had accepted our Investigational New Drug application, or IND, for CLS-AX. In January 2021, we announced that the first patients had been enrolled in our Phase 1/2a clinical trial of CLS-AX, known as OASIS. In ~~March 2021, we completed patient dosing~~OASIS, the primary endpoints were met in ~~Cohort~~Cohorts 1 and 2. CLS-AX was well tolerated with no serious adverse events; there were no treatment emergent adverse events related to aflibercept, CLS-AX or the suprachoroidal injection procedure, no dispersion of ~~OASIS~~drug into the vitreous, and ~~in June 2021, reported that we achieved our safety and tolerability endpoints.~~no adverse events related to IOP, inflammation or vasculitis. In ~~September 2021,~~July 2022, we completed patient enrollment of OASIS and also completed dosing in Cohort 3 in which each patient received a dose of 0.5 mg, and in Cohort 4 in which each patient received a dose of 1.0 mg. Our extension study follows patients in Cohort 2, Cohort 3 and Cohort 4 for up to an additional three-month period.

We enrolled 27 patients in total in all four OASIS cohorts. All patients were highly treatment-experienced wet AMD patients with active disease at screening. Our enrollment allowed us to collect more CLS-AX patient data to help guide our selection of the most appropriate dosing protocol for our planned Phase 2 clinical trial. On November 9, 2022, we reported positive results that included final 3-month data from Cohorts 3 and 4, and interim data from the extension study. CLS-AX demonstrated a positive safety profile in all four cohorts. There were no serious adverse events and no treatment emergent adverse events related to aflibercept,

CLS-AX, or the suprachoroidal injection procedure. There were also no dose limiting toxicities. There were no adverse events related to inflammation, vasculitis or vascular occlusion, and there were no vitreous “floaters” or dispersion of CLS-AX into the vitreous.

In Cohorts 3 and 4, the data showed favorable durability with a meaningful reduction in treatment burden at the 3-month endpoint and to date in the extension study. Of the 16 patients in Cohorts 3 and 4, at the 3-month endpoint, 69% did not receive additional therapy, 92% did not receive additional therapy per protocol criteria, and there was at least a 73% reduction in treatment burden from the average monthly injections in the three months before CLS-AX administration. Of the 12 patients in the extension study, based on interim data as of October 27, 2022, 88% (7/8) of patients did not receive additional therapy to the 5-month endpoint and 75% (3/4) of patients did not receive additional therapy to the 6-month endpoint. Further, in the extension study, there was at least a 90% reduction in treatment burden from the average monthly injections in the six months before CLS-AX administration. In Cohorts 3 and 4, CLS-AX also showed an observable biologic effect with stable mean best corrected visual acuity, or BCVA, stable mean central subfield thickness, or CST, and anatomical signs of TKI biologic effect observed on Optical Coherence Tomography, or OCT, images.

We will continue to follow the patients in the extension study until they all reach the six-month endpoint, and we expect to report that data byin the ~~end~~first quarter of ~~2021. If~~2023. We are actively planning for the ~~data from Cohort~~initiation of a randomized, controlled Phase 2 ~~are positive, we intend to continue the~~ clinical trial ~~with a dose escalation~~ in ~~Cohort 3. We have added a three-month extension study to follow Cohort 2 patients over a longer period~~the first quarter of ~~time.~~2023 in wet AMD and/or diabetic retinopathy.

We have initiated another small molecule program utilizing suprachoroidal administration of an integrin inhibitor ~~suspension.~~suspension, which we refer to as CLS-301. Integrins are multi-functional cell-adhesion molecules that regulate critical cellular processes. Integrins play a role in pathologic processes, such as inflammation, angiogenesis and fibrosis. Integrin inhibition has had some recent preliminary validation in preclinical models and clinical studies of diabetic macular edema and macular degeneration conducted by others. We believe that integrin inhibition could potentially serve as primary therapy, adjunctive therapy to anti-VEGF agents or secondary therapy in refractory cases of diabetic macular edema and macular degeneration. Suprachoroidal delivery of an integrin inhibitor suspension could provide targeting, compartmentalization and durability advantages over topical or intravitreal delivery, similar to what we have observed in other preclinical studies of small molecule suspensions, such as triamcinolone acetonide and axitinib. Therefore, we are assessing ocular tolerability, distribution and pharmacokinetics of our integrin inhibitor suprachoroidal suspension in a series of preclinical studies. ~~These studies~~Our initial preclinical data has shown that the agent is well-tolerated with favorable ocular distribution targeting the chorio-retina, and we have seen encouraging initial signs of durability. We are ~~ongoing.~~

optimizing the formulation and have initiated a second preclinical study. We expect to have results from this study by the end of 2022.

In addition to growing our internal pipeline, we are also focused on collaborating with other companies to provide access to the suprachoroidal space.

During the second half of 2019, we entered into three license and other agreements that we believe validate and expand the reach of our suprachoroidal injection platform. In October 2019, we announced that Bausch + Lomb, a division of Bausch Health Companies, Inc., or Bausch, acquired an exclusive license for the commercialization and development of XIPERE (triamcinolone acetonide ~~suprachoroidal~~injectable suspension) in the United States and Canada. Bausch launched XIPERE in the United States in the first quarter of 2022.

In October 2019, REGENXBIO Inc., or REGENXBIO, exercised its option to license our SCS Microinjector technology for in-office delivery of adeno-associated virus, or ~~AAV,-based~~AAV-based therapeutics to the SCS to potentially treat AMD, diabetic retinopathy and certain other conditions for which chronic anti-VEGF treatment is currently the standard of care. REGENXBIO is currently conducting two multi-center, open-label, randomized, controlled, dose-escalation Phase 2 clinical trials evaluating the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 using our SCS Microinjector technology: ~~the~~a Phase 2 trial entitled AAVIATE for the treatment of wet AMD and a second Phase 2 trial entitled ALTITUDE for the treatment of diabetic retinopathy. REGENXBIO has reported positive initial data from both clinical trials and that it has completed patient enrollment in both ALTITUDE and AAVIATE. In October ~~2021.~~2022, REGENXBIO announced that the interim results for AAVIATE continued to be positive. We expect REGENXBIO to disclose additional data from these trials by the end of 2022.

In July 2019, Aura Biosciences, or Aura, licensed our SCS Microinjector to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma. Aura is currently conducting a Phase 2 trial in choroidal melanoma comprised of an open-label, dose escalation phase and a randomized, masked dose expansion phase. Aura reported positive ~~initial~~interim data on its Phase 2 clinical trial for the treatment of choroidal melanoma in October 2021. Aura has announced the randomized phase of the trial is planned to begin in the second half of 2022 and will serve as the first pivotal trial for the treatment of indeterminate lesions and choroidal melanoma.2022.

In March 2020, we entered into a license agreement, or the Arctic Vision License Agreement, with Arctic Vision (Hong Kong) Limited, or Arctic Vision. Pursuant to the Arctic Vision License Agreement, we granted an exclusive license to Arctic Vision to develop, distribute, promote, market and commercialize XIPERE, subject to specified exceptions, in China, Hong Kong, Macau, Taiwan and South Korea, or the Arctic Territory. ~~In December 2020, Arctic Vision announced approval of its IND for a Phase 3 clinical trial of XIPERE in China and they expect to begin Phase 3 clinical trials later this year.~~

~~In August~~During 2021, we entered into ~~an amendment~~amendments to the Arctic Vision License Agreement to expand the territories covered by the license to include India and the ASEAN Countries (Brunei, Cambodia, Indonesia, Laos,

Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam). and Australia and New Zealand. In ~~September 2021, we entered into a second amendment to the~~December 2020, Arctic Vision ~~License Agreement to expand~~announced approval of its IND for a Phase 3 clinical trial of ARVN001 (known as XIPERE in the U.S.) in China. Arctic ~~Territory to include Australia and~~ ~~New Zealand.~~ ~~We received an aggregate~~Vision has branded ARVN001 as Arcatus. In November 2021, Arctic Vision announced dosing of ~~$3.0 million~~the first patient in ~~consideration~~a Phase 3 clinical trial of ARVN001 for the ~~expansion~~treatment of macular edema associated with uveitis. In March 2022, Arctic Vision announced dosing of the ~~Arctic Territory.~~first patient in a Phase 1 clinical trial of ARVN011 in China for the treatment of diabetic macular edema.

These partnerships enable us to expand the use of our suprachoroidal injection platform to other indications and geographies globally. Under these license agreements, we are eligible to receive up to an aggregate of more than ~~$200~~$230 million in potential future development and sales milestones, as well as and royalties from net sales of covered products. On August 8, 2022, we entered into a Purchase and Sale Agreement pursuant to which we sold our rights to receive royalty and milestone payments due to us related to XIPERE and certain SCS Microinjector license agreements in exchange for up to $65 million, including an initial payment of $32.5 million. The rights to these payments revert to us under the terms and conditions specified in Note 5 to the financial statements.

We have incurred net losses since our inception. In recent years, our operations have consisted primarily of conducting preclinical studies and clinical trials, raising capital and undertaking other research and development initiatives. To date, we have not generated any revenue ~~other than license and other revenue,~~to sustain present activities, and we have primarily financed our operations through public offerings and private placements of our equity securities, issuances of convertible promissory notes, loan agreements and ~~loan~~license agreements. As of September 30, ~~2021,~~2022, we had an accumulated deficit of ~~$274.2~~$278.8 million. We recorded net losses of ~~$4.9~~$7.8 million and ~~$2.4~~$4.9 million for the three months ended September 30, ~~2021~~2022 and ~~2020,~~2021, respectively, and net losses of ~~$18.3~~$23.3 million and ~~$11.1~~$18.3 million for the nine months ended September 30, ~~2021~~2022 and ~~2020,~~2021, respectively. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the necessary development for and obtaining regulatory approval of our product candidates, as well as discovering compounds and developing proprietary formulations to utilize with our SCS Microinjector.

We expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate significant product or license and other revenue unless and until XIPERE is successfully commercialized by ~~its~~our licensees or until we successfully complete development of, obtain regulatory approval for and commercialize additional product candidates, either on our own or together with a third party. Our ~~net losses~~financial results may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials and our expenditures on other research and development activities. ~~Our clinical trial expenses have decreased significantly following our decision to discontinue late-stage clinical trials of XIPERE for indications other than uveitis. However, we~~We expect clinical trial expenses to increase ~~in 2021~~during the remainder of 2022 and into 2023 as a result of our ongoing Phase 1/2a clinical trial of ~~CLS-AX.~~CLS-AX, the preparation of a Phase 2 clinical trial of CLS-AX, as well as continuing our pipeline development. We also will continue our efforts to seek to discover, research and develop additional product ~~candidates and seek regulatory approvals in additional regions for XIPERE for the treatment of macular edema associated with uveitis.~~candidates. Based on our current research and development plans, ~~and expected near-term partnership milestone payments,~~ we expect to have sufficient resources to fund our planned operations into ~~2023.~~

~~We have been actively monitoring the novel coronavirus, or COVID-19, situation and its impact globally.~~ Our financial results for the three and nine months ended September 30, ~~2021~~2022 were not significantly impacted by COVID-19, and we currently do not expect any material impact on our financial results for the remainder of ~~2021. We continue to operate normally with the exception of enabling our employees to work from home and abiding by travel restrictions issued by federal and local governments.~~2022.

As the COVID-19 pandemic continues, we may experience other disruptions that could severely impact our business, results of operations and prospects. The extent to which COVID-19 may impact our business, preclinical development and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, the effectiveness of actions taken in the United States and other countries to contain and treat the disease and the impact of new variants or mutations of the coronavirus, such as the Delta variant.

We have not generated any revenue from the sale of ~~any drugs,~~XIPERE, and we do not expect to generate any until Bausch has reached the first $45 million of net sales (refer to Note 12 to our financial statements included in this Quarterly Report on Form 10-Q) or any other product revenue unless or until ~~XIPERE is commercialized by our licensees or~~ we obtain regulatory approval of and commercialize our other product candidates, either on our own or with a third party. The revenue received under the Bausch license agreement, as well as other certain payments from our licensees, will be recorded as non-cash revenue until we have fulfilled our obligations under the Purchase and Sale Agreement. Our revenue in recent ~~periods~~years has been generated primarily from our license agreements. We are seeking to enter into additional license and other agreements with third parties to evaluate the potential use of our proprietary SCS Microinjector with the third party’s product candidates for the treatment of various eye diseases. These agreements may include payments to us for technology access, upfront license payments, regulatory and commercial milestone payments and royalties.

Research and development expenses consist primarily of costs incurred for the research and development of our preclinical and clinical product candidates, which include:

We expense research and development costs to operations as incurred. These costs include preclinical activities, such as manufacturing and stability and toxicology studies, that are supportive of a product candidate itself. In addition, there are expenses related to clinical trials and similar activities for each program, including costs associated with CROs. Clinical costs are recognized based on the terms of underlying agreements, as well as an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations and additional information provided to us by our vendors about their actual costs occurred. Expenses related to activities that support more than one development program or activity, such as salaries, share-based compensation and depreciation, are not classified as direct preclinical costs or clinical costs and are separately classified as unallocated.

The following table shows our research and development expenses by program for the three and nine months ended September 30, ~~2021~~2022 and ~~2020~~2021 (in thousands).


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020		2022		2021		2022		2021
XIPERE (uveitis program)	$	771	$	781	$	2,646	$	2,048	$	118	$	771	$	315	$	2,646
CLS-AX (wet AMD program)		1,341		478		3,382		1,429		1,529		1,341		4,308		3,382
CLS-301 (DME program)										230		368		860		813
Total		2,112		1,259		6,028		3,477		1,877		2,480		5,483		6,841
Unallocated		3,035		2,231		8,669		7,124		2,760		2,667		9,120		7,856
Total research and development expense	$	5,147	$	3,490	$	14,697	$	10,601	$	4,637	$	5,147	$	14,603	$	14,697

Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended under contracts with research institutions, consultants and CROs that conduct and manage clinical trials on our behalf. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the protocol. If future timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. ItHowever, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of ~~XIPERE or~~ any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our current or future product candidates.

The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that may include, among others:

In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate’s commercial potential.

General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in executive, finance and administrative functions. General and administrative costs historically included commercial pre-launch preparations for XIPERE, and also include facility related costs not otherwise included in research and development expenses, as well as professional fees for legal, patent, consulting, and accounting and audit services.

Other income consists of the gain on the extinguishment of the PPP Loan and accrued interest and interest income earned on our cash and cash ~~equivalents and short-term investments.~~equivalents. Interest income is not considered significant to our consolidated financial statements.

~~Other~~Non-cash Interest Expense on Liability Related to the Sales of Future Royalties

Non-cash interest expense on liability related to the sales of future royalties consists of imputed interest ~~expense incurred under our loan agreements.~~on the carrying value of the liability and the amortization of the related issuance costs.

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the consolidated balance sheets and the reported amounts of expenses during the reporting periods. In accordance with U.S. GAAP, we evaluate our estimates and judgments on an ongoing basis. Significant estimates include assumptions used in the determination of share-based compensation and some of our research and development expenses. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We define our critical accounting policies as those accounting principles generally accepted in the United States of America that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. During the nine months ended September 30, ~~2021,~~2022, there were no significant changes to our critical accounting policies disclosed in our audited financial statements for the year ended December 31, ~~2020,~~2021, which are included in our Annual Report on Form 10-K, as filed with the SEC on March ~~15, 2021.~~11, 2022, other than the liability related to the sales of future royalties discussed in Note 2 to the financial statements.

Results of Operations for the Three Months Ended September 30, ~~2021~~2022 and ~~2020~~2021

The following table sets forth our results of operations for the three months ended September 30, ~~2021~~2022 and ~~2020.~~2021.


	Three Months Ended September 30,						Period-to-Period			Three Months Ended September 30,						Period-to-Period
	2021			2020			Change			2022			2021			Change
	(in thousands)									(in thousands)
License and other revenue	$	3,074		$	3,432		$	(358	)	$	266		$	3,074		$	(2,808	)
Operating expenses:
Research and development		5,147			3,490			1,657			4,637			5,147			(510	)
General and administrative		2,816			2,374			442			2,353			2,816			(463	)
Total operating expenses		7,963			5,864			2,099			6,990			7,963			(973	)
Loss from operations		(4,889	)		(2,432	)		(2,457	)		(6,724	)		(4,889	)		(1,835	)
Other income		2			—			2			194			2			192
Other expense		—			(1	)		1
Non-cash interest expense on liability related to the sales of future royalties											(1,297	)		—			(1,297	)
Net loss	$	(4,887	)	$	(2,433	)	$	(2,454	)	$	(7,827	)	$	(4,887	)	$	(2,940	)

~~Revenue~~License and other revenue. In the three months ended September 30, ~~2021~~2022 and ~~2020,~~2021, we recognized ~~$3.1~~$0.3 million and ~~$3.4~~$3.1 million, respectively, of revenue associated with our license agreements. License revenue for the three months ended September 30, 2021 was primarily a result of a $3.0 million milestone ~~payments~~payment received from Arctic Vision. ~~License revenue for the three months ended September 30, 2020 was primarily a result of a milestone payments received from REGENXBIO.~~

Research and development. Research and development expense ~~increased~~decreased by ~~$1.7~~$0.5 million, from ~~$3.5 million for the three months ended September 30, 2020 to~~ $5.1 million for the three months ended September 30, ~~2021.~~2021 to $4.6 million for the three months ended September 30, 2022. This ~~increase~~ was primarily due to a ~~$0.9~~$0.7 million ~~increase~~decrease in costs related to the uveitis program as XIPERE was approved for commercial sales by the FDA in October 2021 and a $0.1 million decrease in costs related to the CLS-301 program. This was partially offset by an increase of costs of $0.2 million for the ~~for~~ CLS-AX program, including costs for OASIS, a Phase 1/2a clinical trial of ~~CLS-AX and a $0.3 million increase in employee related costs. In addition, there was a $0.3 million increase in costs in our other programs.~~

General and administrative. General and administrative expenses ~~increased~~decreased by ~~$0.4~~$0.5 million, from $2.8 million for the three months ended September 30, 2021 to $2.4 million for the three months ended September 30, ~~2020~~2022. This was primarily attributable to ~~$2.8~~a $0.3 million decrease in employee related costs related to share based compensation and a $0.1 million decrease in professional fees.

Other income. Other income for the three months ended September 30, ~~2021. This~~2022 was comprised of interest income from cash and cash equivalents. Other income for the three months ended September 30, 2021 was primarily ~~attributable~~comprised of the gain on the extinguishment of debt from the forgiveness of the PPP Loan and accrued interest.

Non-cash interest expense from liability related to ~~an increase in employee~~the sales of future royalties. Non-cash interest expense for the three months ended September 30, 2022 was comprised of imputed interest on the liability related to the sales of future royalties and the amortization of the associated issuance costs.

Results of Operations for the Nine Months Ended September 30, ~~2021~~2022 and ~~2020~~2021

The following table sets forth our results of operations for the nine months ended September 30, ~~2021~~2022 and ~~2020.~~2021.


	Nine Months Ended September 30,						Period-to-Period			Nine Months Ended September 30,						Period-to-Period
	2021			2020			Change			2022			2021			Change
	(in thousands)									(in thousands)
License and other revenue	$	3,888		$	7,883		$	(3,995	)	$	997		$	3,888		$	(2,891	)
Operating expenses:
Research and development		14,697			10,601			4,096			14,603			14,697			(94	)
General and administrative		8,525			8,107			418			8,601			8,525			76
Total operating expenses		23,222			18,708			4,514			23,204			23,222			(18	)
Loss from operations		(19,334	)		(10,825	)		(8,509	)		(22,207	)		(19,334	)		(2,873	)
Other income		1,001			—			1,001			220			1,001			(781	)
Other expense		—			(273	)		273
Non-cash interest expense on liability related to sales of future royalties											(1,297	)		—			(1,297	)
Net loss	$	(18,333	)	$	(11,098	)	$	(7,235	)	$	(23,284	)	$	(18,333	)	$	(4,951	)

~~Revenue~~License and other revenue. In the nine months ended September 30, ~~2021~~2022 and ~~2020,~~2021, we recognized ~~$3.9~~$1.0 million and ~~$7.9~~$3.9 million, respectively, of revenue associated with our license agreements. License revenue for the nine months ended September 30, 2021, was primarily a result of $3.8 million in milestone payments ~~of $3.8 million~~ received from Arctic Vision. ~~License revenue for the nine months ended September 30, 2020 was primarily a result of milestone payments of $4.3 million received from Arctic Vision and $3.0 million received from REGENXBIO.~~

Research and development. Research and development expense ~~increased~~decreased by ~~$4.1 million,~~$94,000, from ~~$10.6~~$14.7 million for the nine months ended September 30, ~~2020~~2021 to ~~$14.5~~$14.6 million for the nine months ended September 30, 2022. This decrease is primarily a result of a $2.3 million decrease in costs related to the uveitis program as XIPERE was approved for commercial sales by the FDA in October 2021. ~~This increase~~The decrease was ~~primarily due to~~offset by a ~~$2.0~~$0.9 million increase in ~~costs for~~ the ~~for~~ CLS-AX program, including costs for OASIS, a Phase 1/2a clinical

trial of CLS-AX and the OASIS Extension, a $0.3 million increase in costs of manufacturing the SCS Microinjector and a $0.6 million increase in ~~costs related drug manufacturing for XIPERE. In addition,~~ employee related costs ~~increased $1.1 million during the same period.~~due to an increase in headcount including recruiting costs.

General and administrative. General and administrative expenses increased by ~~$0.4~~$76,000 from $8.5 million for the nine months ended September 30, 2021 ~~and 2020.~~to $8.6 million for the nine months ended September 30, 2022. This ~~increase~~ was primarily attributable to a ~~result of a $0.8~~$0.2 million increase in ~~employee related~~patent costs ~~partially~~ offset by a ~~$0.3~~$0.2 million decrease in ~~patent costs and professional fees.~~employee related costs.

Other income. Other income for the nine months ended September 30, 2022 was comprised of interest income from cash and cash equivalents. Other income for the nine months ended September 30, 2021 was primarily comprised of the gain on the extinguishment of debt from the forgiveness of the PPP Loan and accrued interest.

~~Other~~Non-cash interest expense from liability related to the sales of future royalties. ~~Other~~Non-cash interest expense for the nine months ended September 30, ~~2020 primarily consisted~~2022 was comprised of imputed interest on ~~long-term debt,~~the liability related to the sales of future royalties and the amortization of ~~financing costs,~~ the ~~accretion of warrants and the final payment related to our prior loan agreement.~~associated issuance costs.

We have funded our operations primarily through the proceeds of public offerings of our common stock, sales of convertible preferred stock, ~~and~~ the issuance of long-term ~~debt.~~debt and license agreements. As of September 30, ~~2021,~~2022, we had cash and cash equivalents of ~~$25.2~~$53.4 million. We invest any cash in excess of our immediate requirements primarily with a view to liquidity and capital preservation. As of September 30, ~~2021,~~2022, our funds were held in cash and money market funds.

On August 8, 2022, or the Closing Date, we, through our wholly-owned subsidiary Clearside Royalty LLC, a Delaware limited liability company, or Royalty Sub, entered into a Purchase and Sale Agreement with entities managed by HealthCare Royalty Management, LLC, or HCR, pursuant to which Royalty Sub sold to HCR certain of its rights to receive royalty and milestone payments payable to Royalty Sub under the Arctic Vision License Agreement, Bausch License Agreement, that certain License Agreement, effective as of July 3, 2019, by and between us and Aura Biosciences, Inc., that certain Option and License Agreement, dated as of August 29, 2019, by and between REGENXBIO Inc. and us, and any and all out-license agreements following the Closing Date for, or related to XIPERE or the SCS Microinjector technology to be used in connection with compounds or products of any third parties delivered, in whole or in part, by means of the SCS Microinjector technology, excluding, for the avoidance of doubt, any in-licensed or internally developed therapies following the Closing Date, in exchange for up to $65 million. Under the terms of the Purchase and Sale Agreement, Royalty Sub received a payment of $32.1 million, representing the $32.5 million to which we were entitled less certain expenses. There were additional issuance costs of $1.5 million related to the Purchase and Sale Agreement resulting in net proceeds of $30.6 million. An additional $12.5 million was deposited in an escrow account by HCR to be released to Royalty Sub upon attainment of a pre-specified XIPERE sales milestone achieved no later than March 31, 2024. The terms of the Purchase and Sale Agreement also provide for an additional $20 million milestone payment to Royalty Sub upon attainment of a second pre-specified sales milestone related to 2024 XIPERE sales.

In April 2020, we entered into a loan agreement with Silicon Valley Bank under the terms of which Silicon Valley bank loaned us $1.0 million, or the PPP Loan, pursuant to the Paycheck Protection Program, or PPP, under the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act. In accordance with the requirements of the CARES Act, we used the proceeds primarily for payroll costs and other eligible expenses. The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. On January 11, 2021, we received notification from Silicon Valley Bank that the PPP loan was forgiven in full, including approximately $7,000 of accrued interest.

In March 2020, ~~we entered into the Arctic License Agreement, pursuant to which~~ Arctic Vision ~~has~~paid us an upfront payment of $4.0 million. In December 2021, we received a milestone payment of $4.0 million following receipt of FDA approval of XIPERE in the United States. In addition, Arctic Vision agreed to pay us up to a total of ~~$35.5 million. This amount includes an upfront payment of $4.0 million, which we received in March 2020, as well as an aggregate of up to $31.5~~$22.5 million in ~~potential~~ development ~~milestone payments for specified events, including $4.0 million upon regulatory approval of XIPERE in the United States~~ and ~~potential~~ sales milestone ~~payments for achievement of specified levels of net~~

~~sales.~~payments. Further, during the applicable royalty term, ~~we will also be entitled~~Arctic Vision agreed to ~~receive~~pay us tiered royalties of 10-12% of net sales in the Arctic Territory, subject to customary reductions. In August 2021, we entered into an amendment to the Arctic Vision License Agreement to expand the territories covered by the license to include India and the ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam). In September 2021, we entered into a second amendment to the Arctic Vision License Agreement to expand the Arctic Territory to include Australia and New Zealand. We received an aggregate of $3.0 million in consideration for the expansion of the Arctic Territory.

In October 2019, we announced that Bausch acquired an exclusive license for the commercialization and development of XIPERE in the United States and Canada. On October 25, 2021, we announced that the FDA approved XIPERE for the treatment of macular edema associated with uveitis. We ~~are entitled to receive~~received $5.0 million from Bausch ~~within 30 days of~~in November 2021 relating to the FDA approval of XIPERE, and in January 2022, we ~~are eligible to receive~~received an additional $10.0 million upon completion of pre-launch activities for XIPERE. Bausch ~~expects to launch~~launched XIPERE in the United States in the first quarter of 2022.

We have entered into an at-the-market sales agreement, or the ATM agreement, with Cowen and Company LLC, or Cowen, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0 million through Cowen acting as our sales agent. ~~During the nine months ended September 30, 2021, we sold 2.9 million shares of our common stock for net proceeds of $12.2 million under the ATM agreement.~~ As of September 30, ~~2021,~~2022, there was $14.4 million available for sales of our common stock under the ATM agreement.

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, research and development costs to build our product candidate pipeline, legal and other regulatory expenses and general overhead costs. In addition, we have certain contractual obligations for future payments. Refer to Note 10 to our consolidated financial statements included in this Quarterly Report on Form 10-Q.

The successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of CLS-AX or any future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from product sales. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that candidate.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. Other than potential payments we may receive under our license and other agreements, we do not currently have any committed external source of funds, though, as described above, we may also be able to sell our common stock under the ATM agreement with Cowen subject to the terms of that agreement and depending on market conditions. We expect that we will require additional capital to fund our ongoing operations. Additional funds may not be available to us on a timely basis, on commercially reasonable terms, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 ~~pandemic.~~pandemic, the Russian Federation invasion of Ukraine and macroeconomic conditions such as inflation. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through additional collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, including any future collaboration or licensing arrangement for XIPERE outside of the territories in which we have previously licensed or granted options to license XIPERE, we may be required to relinquish additional rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

We also incur costs as a public company, including costs and expenses for fees to members of our board of directors, accounting and finance personnel costs, directors and officers insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with reporting requirements under the Exchange Act and rules implemented by the SEC and Nasdaq.

We have suffered recurring losses and negative cash flows from operations since inception and anticipate incurring additional losses until such time, if ever, that we can ~~obtain FDA approval to market and then~~ generate significant milestone payments and

royalties from XIPERE and other licensing arrangements or revenues from other product candidates. We will need additional financing to fund our operations. Our plans primarily consist of raising additional capital, potentially in a combination of equity or debt financings, monetizing royalties, or restructurings, or potentially entering into additional collaborations, partnerships and other strategic arrangements.

Based on our ~~current plans and forecasted expenses, we expect that our~~ cash and cash equivalents as of the filing date, November ~~10, 2021,~~9, 2022, our current plans and forecasted expenses we expect that we will ~~enable us~~be able to fund our planned operating expenses and capital expenditure requirements into 2023. This estimate assumes receipt of the $9.0 million of milestone payments that we are entitled receive from our licensees as a result of FDA approval of XIPERE. In addition, the estimate assumes receipt of the $10.0 million milestone payment that we are entitled to receive from Bausch upon completion of pre-launch activities for XIPERE.2024. We have based

this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. We will require additional capital in order to complete clinical development of CLS-AX.

The following is a summary of the net cash flows provided by (used in) our operating, investing and financing activities (in thousands):


	Nine Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2022			2021
Net cash (used in) provided by:
Net cash provided by (used in):
Operating activities	$	(15,787	)	$	(8,684	)	$	(7,758	)	$	(15,787	)
Investing activities		—			(55	)		(155	)		—
Financing activities		23,617			983			30,758			23,617
Net change in cash and cash equivalents	$	7,830		$	(7,756	)	$	22,845		$	7,830

During the nine months ended September 30, ~~2021 and 2020,~~2022, our operating activities used net cash of ~~$15.8~~$7.8 million and ~~$8.7~~$15.8 million, respectively. The ~~use of~~net cash used in ~~each period primarily resulted from our net losses. The increase in net loss to $18.3 million for~~ the nine months ended September 30, ~~2021 as compared~~2022 was primarily due to ~~$11.1~~research and development expenses related to the preclinical and clinical programs and general and administrative expenses offset by the receipt of the $10.0 million milestone payment received from Bausch in connection with pre-launch activities for XIPERE. The net cash used in the nine months ended September 30, ~~2020~~2021 was primarily attributable to higher research and development expenses related to the preclinical and clinical CLS-AX ~~program in the nine months ended September 30, 2021 and higher license revenue in the nine months ended September 30, 2020.~~program.

During the nine months ended September 30, ~~2020,~~2022, our investing activities used net cash ~~used in investing activities was $55,000, due to~~of $0.2 million for the ~~purchase~~acquisition of property and equipment.

During the nine months ended September 30, 2022 and 2021, our net cash provided by financing activities was $30.8 million and $23.6 ~~million. This~~million, respectively. The cash provided by financing activities for the nine months ended September 30, 2022 primarily consisted of $30.6 million of proceeds received from the Purchase and Sale Agreement, net of issuance costs. The cash provided by financing during the nine months ended September 30, 2021 primarily consisted of $11.1 million of net proceeds from the sale of shares of our common stock in a registered direct offering and $12.2 million of net proceeds from the sale of shares of our common stock under the ATM agreement. During the nine months ended September 30, 2020, our net cash provided by financing activities consisted of $5.1 million of net proceeds from the sale of shares of our common stock under the ATM agreement and $1.0 million of proceeds from the PPP Loan, partially offset by a payment of $5.3 million under our credit facility.

~~We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.~~

~~See Item 1, “Financial Statements – Note 2, Significant Accounting Policies” for a discussion of recent accounting pronouncements and their effect on us.~~

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s

management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report at the reasonable assurance level.

There has been no change in our internal control over financial reporting during the quarter ended September 30, ~~2021~~2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal control over financial reporting. ~~However, we continue to monitor and assess the potential impact of the COVID-19 pandemic on our control environment.~~

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. These risks could be amplified by the COVID-19 pandemic and its potential impact on the global economy generally and our business and industry in particular. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described below and in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020,~~2021, filed with the Securities and Exchange Commission on March ~~15, 2021. There~~11, 2022. Except as described below, there have been no material changes to the risk factors described in that report.

Our agreements with HCR contain various covenants and other provisions, which, if violated, could materially adversely affect our financial condition.

On August 8, 2022, we, through Royalty Sub, entered into the Purchase and Sale Agreement, with HCR pursuant to which we sold our rights to royalty and milestone payments due to us from XIPERE and certain license agreements related to our SCS Microinjector, or the Royalties, subject to a cap of 2.5 times the total purchase price paid by HCR under the Purchase and Sale Agreement, which cap can be increased to 3.4 times under certain circumstances. Under the terms of the Purchase and Sale Agreement, Royalty Sub received an initial payment of $32.5 million, less certain expenses. An additional $12.5 million was placed in an escrow account to be released to Royalty Sub upon attainment of a pre-specified XIPERE sales milestone achieved no later than March 31, 2024. The terms of the Purchase and Sale Agreement also provide for an additional $20 million milestone payment to Royalty Sub upon attainment of a second pre-specified sales milestone related to 2024 XIPERE sales.

In connection with the Purchase and Sale Agreement, we entered into a Contribution and Servicing Agreement with Royalty Sub, pursuant to which we assigned the Arctic Vision License Agreement, Bausch License Agreement, Aura License Agreement, REGENXBIO License Agreement, our license agreement with Emory University and The Georgia Tech Research Corporation and related intellectual property rights, or collectively the Contributed Assets, to Royalty Sub. The Contribution and Servicing Agreement contains various representations and warranties, covenants, indemnification obligations and other provisions related to the contribution of the Contributed Assets and our maintenance and servicing obligations with respect to the same.

In connection with the Purchase and Sale Agreement, we also entered into a Pledge and Security Agreement with HCR. The Pledge and Security Agreement contains various representations, warranties and covenants, and includes a limited recourse guaranty of Royalty Sub’s obligations under the Purchase and Sale Agreement which is secured by the pledge in favor of HCR all of the capital stock of Royalty Sub. HCR is entitled to foreclose on the capital stock of Royalty Sub following the occurrence of certain remedies events, including, without limitation, a bankruptcy of us, our failure of to perform our obligations under the Contribution and Servicing Agreement or in the event of a change of control of us, any failure to make the payment required under Section 2.3 of the Purchase Agreement within the time period required thereunder. Such foreclosure, if it were to occur, could have a material adverse effect on our financial condition as HCR, by virtue of owning Royalty Sub, would own the Royalties and the Contributed Assets.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Delaware	45-2437375
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
900 North Point Parkway, Suite 200 Alpharetta, GA	30005
(Address of principal executive offices)	(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	CLSD	The Nasdaq Stock Market LLC


		Page
	PART I - FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (unaudited)
	Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021	3
	~~Balance Sheets as of September 30, 2021 and December 31, 2020~~	3
	Consolidated Statements of Operations for the three and nine months ended September 30, ~~2021~~2022 and ~~2020~~2021	4
	Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, ~~2021~~ 2022 and ~~2020~~2021	5
	Consolidated Statements of Cash Flows for the nine months ended September 30, ~~2021~~2022 and ~~2020~~2021	6
	Notes to the Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1516
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2325
Item 4.	Controls and Procedures	2325
	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	2527
Item 1A.	Risk Factors	2527
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2527
Item 6.	Exhibits	2628
Signatures		2729


Royalty purchase and sale agreement effective August 8, 2022	$	32,500
Issuance costs		(1,862	)
Non-cash interest expense		1,297
Balance at September 30, 2022	$	31,935

Effective interest rate		26.5	%


				Weighted Average					Weighted Average
	Number of			Grant Date		Number of			Grant Date
	Shares			Fair Value		Shares			Fair Value
Non-vested RSUs outstanding at December 31, 2020		767,271		$	1.78
Non-vested RSUs outstanding at December 31, 2021							1,317,347		$	3.58
Granted		965,344			4.01		648,460			2.19
Vested		(415,268	)		1.27		(375,331	)		3.44
Non-vested RSUs outstanding at September 30, 2021		1,317,347			3.58
Forfeited							(127,544	)		3.04
Non-vested RSUs outstanding at September 30, 2022							1,462,932			3.04


	September 30,		December 31,		September 30,		December 31,
	2021		2020		2022		2021
Accrued research and development	$	1,594	$	234	$	1,453	$	1,083
Accrued employee costs		1,145		1,132		1,249		1,854
Accrued professional fees		82		56		43		30
Accrued expense		175		160		200		345
	$	2,996	$	1,582	$	2,945	$	3,312


	Three and Nine Months Ended September 30,
	2022		2021
Outstanding stock options		7,218,605		5,858,739
Non-vested restricted stock units		1,462,932		1,317,347
Stock purchase warrants		29,796		29,796
		8,711,333		7,205,882


Exhibit No.		Description

3.1		Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783) filed with the SEC on June 7, 2016).

3.2		Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37783) filed with the SEC on June 23, 2022).

3.3		Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37783) filed with the SEC on June 7, 2016).

10.1*#+^		~~First Amendment to the License~~Purchase and Sale Agreement, by and ~~between the Registrant~~among Clearside Royalty LLC, Healthcare Royalty Partners IV, L.P. and ~~Arctic Vision (Hong Kong) Limited,~~HCR Collateral Management, LLC (in its capacity as agent for Purchaser), dated as of August ~~15, 2021.~~8, 2022.

~~10.2*#~~		~~Second Amendment to the License Agreement by and between the Registrant and Arctic Vision (Hong Kong) Limited, dated as of September 9, 2021.~~

10.3*		~~Second Amendment to the License Agreement by and between the Registrant and Bausch + Lomb Ireland Limited (as assignee of Bausch Health Ireland Limited), dated as of September 27, 2021.~~

31.1*		Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.

31.2*		Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act.

32.1**		Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act.

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)


*	Filed herewith.
**	These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
#^	~~Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential~~Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and are the type that the registrant treats as private or confidential.
+	Certain of the exhibits and schedules to this exhibit have been omitted ~~by means~~in accordance with Regulation S-K Item 601. The registrant agrees to furnish a copy of ~~marking such portions with asterisks [***] as~~all omitted exhibits and schedules to the ~~identified confidential portions (i) are not material and (ii) the Registrant customarily and actually treats that information as private or confidential.~~SEC upon its request.


	Clearside Biomedical, Inc.

Date: November ~~10, 2021~~9, 2022	By:	/s/ Charles A. Deignan
		Charles A. Deignan
		Chief Financial Officer
		(On behalf of the Registrant and as Principal Financial Officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company